Innovative NeurovaScular Product surveIllance REgistry (INSPIRE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Intracranial Ica Aneurysm
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Neurovascular PSR Registry:
    1. Patient or legally authorized representative (LAR) provides authorization and written informed consent
    2. Patient has, or is intended to receive or be treated with, an eligible Medtronic product
    3. Patient is consented within the enrollment window of the therapy received, as applicable
    Post Approval Study (PAS) Addendum:
    1. Patient or legally authorized representative (LAR) provides authorization and written informed consent and agrees to comply with the study procedures
    2. Patient has already been selected for endovascular treatment of the target aneurysm with the Pipeline™ Shield Device as the appropriate treatment

You may not be eligible for this study if the following are true:

  • Neurovascular PSR Registry:
    1. Patient who is, or is expected to be, inaccessible for follow-up
    2. Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the PSR results
    Post Approval Study (PAS) Addendum:
    1. Patient is contraindicated for the device or procedure per the Pipeline™ Shield Device IFU
    2. The Investigator determined that the health of the patient may be compromised by the patient’s enrollment
    3. Patient is enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.